AM-Pharma inks $133 mln
Netherlands-based AM-Pharma, a clinical-stage biopharmaceutical company focused on developing a treatment for acute kidney injury, has raised $133 million in funding. LSP and Andera Partners led the round.
16 July 2019•1 min read
